Data / Drug companies / Sinopep-Allsino Biopharmaceutical Co., Ltd.
Sinopep-Allsino Biopharmaceutical Co., Ltd.: 19 products in the FDA NDC directory, labeler code 76177
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sinopep-Allsino Biopharmaceutical Co., Ltd. (labeler code 76177) lists 19 products in the FDA National Drug Code Directory. By type: 19 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on September 1, 2026.
The request: Watch Sinopep-Allsino Biopharmaceutical Co., Ltd. (FDA labeler code 76177): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 76177
- Products in commercial distribution
- 19
- Packages
- 95
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- June 19, 2015
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 14 | 73.7% |
| Bulk ingredients for compounding | 5 | 26.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 19 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 19 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Retatrutide | 76177-055 | Powder | Bulk ingredients for compounding | September 1, 2026 |
| Tirzepatide | 76177-501 | Powder | Bulk ingredients | November 1, 2023 |
| Semaglutide | 76177-022 | Powder | Bulk ingredients | November 1, 2023 |
| Tirzepatide | 76177-192 | Powder | Bulk ingredients for compounding | January 10, 2023 |
| Tirzepatide | 76177-192 | Powder | Bulk ingredients | January 10, 2023 |
| Semaglutide | 76177-521 | Powder | Bulk ingredients for compounding | March 1, 2021 |
| Semaglutide | 76177-054 | Powder | Bulk ingredients | March 1, 2021 |
| Fulvestrant | 76177-053 | Powder | Bulk ingredients | March 1, 2020 |
| Octreotide acetate | 76177-119 | Powder | Bulk ingredients | December 31, 2019 |
| Cetrorelix acetate | 76177-021 | Powder | Bulk ingredients | June 1, 2019 |
| Liraglutide | 76177-520 | Powder | Bulk ingredients for compounding | March 1, 2019 |
| Liraglutide | 76177-118 | Powder | Bulk ingredients | March 1, 2019 |
| Liraglutide | 76177-018 | Powder | Bulk ingredients | February 1, 2019 |
| Dinitolmide | 76177-180 | Powder | Bulk ingredients | January 31, 2019 |
| Decoquinate | 76177-100 | Powder | Bulk ingredients | October 1, 2018 |
| Bivalirudin | 76177-333 | Powder | Bulk ingredients for compounding | January 9, 2018 |
| Bivalirudin | 76177-001 | Powder | Bulk ingredients | January 9, 2018 |
| Eptifibatide | 76177-009 | Powder | Bulk ingredients | May 16, 2016 |
| Lanreotide acetate | 76177-017 | Powder | Bulk ingredients | June 19, 2015 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.